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A B ST R AC T  
 
Aim: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the 
gastrointestinal tract. Armed Forces Institute of Pathology (AFIP) criteria which is the basis of our 
study, is also known as Miettinen’s criterion is used in classification of GIST. Lymphocyte-monocyte 
ratio (LMR), and platelet lymphocyte ratio (PLR) have been shown as novel markers in chronic 
systemic inflammatory response, therefore, we aimed to study LMR levels of the subjects with 
moderate to high risk GIST and to compare to those in the subjects with low or very low risk GIST. 
Methods: Thirty GIST patients who underwent surgery were retrospectively evaluated. Patients were 
divided into two groups according to the AFIP risk scoring system: the first group (group 1) included 
very low and low risk patients and the second group (group 2) included moderate and high risk 
patients. Inflammatory indicators; LMR and PLR of the groups were compared. 
Results: LMR value was higher in Group 1 (5.25 ± 2.55) than the LMR of group 2 (2.92 ± 1.76). 
PLR value was significantly lower in group 1 (139.68) compared to the PLR of group 2 (185.04).  
Conclusion: We think that LMR is effective in identifying low and very low risk patients compared 
to AFIP. From this point of view, we suggest that LMR can identify high and medium risk patients 
by excluding low and very low risk patients and may be an independent risk factor in GIST scoring 
systems.  
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Introduction 
Gastrointestinal stromal tumors (GIST) are the 
most common mesenchymal tumors of the 
gastrointestinal tract. The incidence of GIST is 
14-20 per ml [1]. GIST are myenteric plexus 
small settled a kit positive cell population Cajall 
originate from cell neoplasms [2]. The main 
cause of GIST is presence of abnormal tyrosine 
protein kinase, which is known as CD117 that 
causes uncontrolled growth of gastrointestinal 
cells. GIST can occur anywhere in the 
gastrointestinal tract, such as, gastric (50-60%) 
and small bowel (30-35%), and less frequently 
in the colon and the rectum (5%). It is very rare 
(1%) in esophagus  [3] .  
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Although it may occur at any age, advanced age 
is a risk factor for GIST. The average age 
reported in previous studies is 60 years. 
Different risk classification systems are used in 
GIST. Armed Forces Institute of Pathology 
(AFIP) criteria, which is the basis of our study, 
is also known as Miettinen’s criterion is useful 
in risk stratification in GIST [1].  
Virchow stated that there is a connection 
between cancer and inflammation and that 
lymphocytic infiltrate in the areas of chronic 
inflammation may constitute the origin of 
cancer [4]. Indeed, chronic inflammation has 
been documented in different types of cancer 
[5]. Since the systematic inflammatory 
response (SIR) indirectly reflects the host 
immune status, it probably reflects the 
prognosis of various malignancies, including 
gastrointestinal cancers. Alternatively, the 
lymphocyte-monocyte ratio (LMR), which is 
the ratio of monocyte count in peripheral blood 
to lymphocyte count, has been shown as a novel 
marker of chronic SIR. This is because 
monocytes, monocytes-derived macrophages 
and lymphocytes play primary role in chronic 
inflammation rather than acute inflammation 
[6]. Some studies have reported that LMR was 
a prognostic factor for disease-free survival and 
overall survival in colorectal cancer [7] and 
pancreatic cancer [8].  
In this study, we investigated the effect of 
hemogram parameters obtained from 
preoperative blood count tests of subjects with 
GIST in predicting low and very low risk GIST 
patients according to AFIP scoring. 
 
Materials and Methods 
Thirty patients with gastrointestinal stromal 
tumors who underwent surgery in the general 
surgery clinic of Bolu Abant Izzet Baysal 
University (BAIBU) Medical Faculty between 
2012 and 2018 were retrospectively evaluated. 
The study was approved by BAIBU, Clinical 
Research Ethics Committee, decision number 
2016/369, dated 01/06/2016. All procedures 
performed in this study were in accordance with 
the ethical standards of the institutional and/or 
national research committee and with the 1964 
Helsinki declaration, as revised in 2000.  
When the files were retrospectively examined, 
hemogram values were included in the study 
seven days before the operation date. 
Preoperative hemogram parameters white 
blood cells (WBC), neutrophil, lymphocyte, 
monocyte, and platelet values were recorded. 
The ratio of neutrophil to lymphocyte ratio 
(NLR) by the ratio of neutrophil count to 
lymphocyte count, and lymphocyte monocyte 
ratio (LMR) by ratio of lymphocyte count to 
monocyte count; the ratio of platelet count to 
lymphocyte count provided the platelet 
lymphocyte ratio (PLR); monocyte leucocyte 
ratio (MWR) was obtained by ratio of 
monocyte value to leukocyte value. 
Postoperative pathology specimens of the 
patients were examined. The patients were 
categorized according to the AFIP [9, 10] risk 
classification in the pathology specimens. This 
criterion also considers the anatomical region 
of the tumor. According to these criteria, in 
gastric GIST ≤10 cm and 5 mitoses per 50 HPF 
have a low risk for metastasis, however 50 HPF 
>5 mitosis and> 5 cm diameter have a high risk 
for metastasis in gastric GIST. On the other 
hand, regardless of mitotic rate, all intestinal 
GIST greater than 5 cm are at least moderately 
at risk for metastases, and the risk of metastasis 
is known to be high in all> 5 mitoses per 50 
HPF. Intestinal GIST ≤5 mitosis per 50 HPF 
and ≤5 cm metastasis risk is low. 
Immunohistochemical features in the pathology 
report were removed and their microscopic and 
macroscopic features were examined. Thirty 
patients were divided into two groups 
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according to the AFIP risk scoring system: the 
group 1 included very low and low risk patients 
and the group 2 included moderate and high risk 
patients. Inflammatory indicators LMR, PLR 
and MWR were compared between the groups. 
Since the number of cases is limited, all patients 




Kolmogorov-Smirnov test was used to check 
whether the variables were normally distributed 
or not. While t-test was applied for variables 
showing normal distribution; Mann-Whitney U 
tests were used for the analysis of variables not 
showing normal distribution. The receiver-
operating characteristic (ROC) curve was used 
to identify the optimal cut-off values of 
statistically significant variables that identified 
the low-risk patient group. All the analyses 
were performed with the Statistical Package for 
Social Sciences 25.0 for Windows (SPSS Inc., 
Chicago, Illinois, USA) and the results with a 




The demographic information and 
clinicopathological characteristics of 30 
patients with GIST are shown in Table 1. The 
age of the study population was 65.63 (29-86) 
years. The age of the group 1 was 65.21 (41-85) 
years and the age of the group 2 was 66 (29-86) 
years (p = 0.75). According to gender, 13 of 30 
patients were female and 17 were male. It was 
seen that 8 of the patients in the group 1 were 
male and 5 of them were female and 12 of the 
patients in the group 2 were male and 5 of them 
were female. There was no significant 
difference between groups according to the 
gender of the subjects (p = 0.078).  
Table 1. The demographic information and 
clinicopathological characteristics of 30 







































Variable n (%) 
Median age (range, yr) 66 (29-86) 
Gender 
     Female 




According to AFIP 
classification 
     Very Low Risk 
     Low Risk 
     Moderate 
     High Risk 









Tumor size (cm) 
      ≤2 
      >2 and ≤5 
      >5 and ≤10 







      Stomach 
      Jejunum/ileum 






      ≤5/50HPFs 





      Fusiform Cell 
      Mixed 






      Yes  





      Yes 





      Yes 
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When the localization of GIST was examined, 
it was found that 18 cases were located in the 
stomach, 12 cases were located in the jejunum / 
ileum, colon and rectum. One of the patients in 
Group 1 had GIST located in the small 
intestine, 12 of them were in the stomach, 11 of 
the patients in group 2 were located outside the 
stomach, and 6 of them were located in the 
stomach.  
LMR value was significantly higher in group 1 
patients (5.25 ± 2.55) than group 2 patients 
(2.92 ± 1.76) in the preoperative hemogram 
parameters (p = 0.006). PLR of Group 1 
(139.68) (77.15-370) (p=0.016) was 
significantly lower than the PLR of Group 2 
(185.04) (104.3-430.6) (Table 3). In addition, 
MWR of group 1 (0.05) (0.03-0.16) was 
significantly lower than the MWR of group 2 
(0.08) (0.04-0.17) (p = 0.014).  
 
Table 2.   Comparisons of preoperative blood test 










LMR: lymphocyte monocyte ratio. MWR: 
monocyte leucocyte ratio. NLR: neutrophil to 
lymphocyte ratio. PLR: platelet lymphocyte ratio.  
 
ROC analysis was performed to determine the 
cut-off values of significant LMR values. In 
patients with GIST, the LMR value above 1.609 
level (Figure 1) can be predicting with 84% 
sensitive and 77% specifically the low or very 
low risk patients. Area value under the curve 
















Figure 1.  ROC analysis of lymphocyte monocyte 
ratio (LMR) value. 
 
Discussion 
In this study, LMR was found to be 
significantly higher in group 1(low and very 
low-risk GIST) patients compared to group 2 
(moderate and high-risk GIST) patients. In 
addition, LMR value above 1.609 had 84% 
sensitivity and 77% specificity for low and very 
low-risk GIST patients. Studies in GIST have 
focused on determining recurrence or 
prognosis. Discussions have suggested scoring 
systems or nomograms to better predict the risk 
and prognosis of recurrence. These scoring 
systems or nomograms include mitotic activity, 
tumor size, and tumor site [10-12] , which are 
independent prognostic factors. We also used 
the AFIP scoring system in our study. 
Gastric GIST have a lower risk of relapse than 
non-gastric GIST cases [3, 11]. In our study, 
tumor site was significantly different between 
groups 1 and 2. The rate of extra-gastric GIST 
was higher in the patients with moderate and 
high risk group (p = 0.002). 
The use of these criteria aims to identify 
patients who may benefit from adjuvant 
Variables 
Group 1  
(n=13) 
Group 2  
(n=17) 
p 
Neutrophil 4.34(2.29-9.08) 4.85(2.49 -0.74) 0.676 
LMR 5.25(±2.55) 2.92 (±1.76) 0.006 
MWR (0.05) (0.03-0.16) (0.08) (0.04-0.17) 0.014 
NLR 4.23 (1.25 - 28.3) 3.84 (1.30 – 8.84) 0.098 
PLR 139.6 (77 - 370) 185.04 (104 - 430 0.016 
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systemic therapy to reduce recurrence. In our 
study, the AFIP scoring which we evaluated 
also provides guidance in predicting recurrence 
after surgery in patients. Patients with low-risk 
scoring systems usually have positive outcomes 
and do not require adjuvant therapy [3]. 
Recent studies aim to predict the prognosis of 
GIST with inflammatory indicators in blood 
parameters. Kargin and colleagues [13] 
evaluated the relationship between elevated 
blood neutrophil-lymphocyte ratio and 
prognosis in GIST patients. The authors found 
that this rate increased significantly in high-risk 
patients and was associated with short survival 
[13]. In our study, we found that high LMR 
values predict low-risk GIST patients. 
Studies have shown that systemic inflammatory 
response and platelets, especially NLR ratio, 
dNLR (derived Neutrophil Lymphocyte) ratio, 
LMR ratio and PLR ratio, can predict important 
clinical outcomes in a wide range of cancers.  
PLR is also predictive of poor diabetic control 
in patients with type 1 diabetes mellitus, 
characterized by low inflammatory burden 
[14]. Chronic inflammation occurs locally in 
solid cancers and contributes to tumor growth 
and progression [15]. LMR, esophageal 
squamous cell carcinoma [16] and stomach 
[17], colorectal [18] cancers such as cancers in 
patients with advanced T stage prognostic 
importance has been made in studies. In 
addition, LMR was found to correlate primarily 
with local cancer progression rather than 
metastasis and was associated with T stage, 
similar to other inflammatory markers, but not 
always with N stage [6]. In the study of LMR in 
soft tissue sarcomas undergoing curative 
surgery, it was shown to be an independent 
prognostic factor in patients [6, 19]. In our 
study, we found that high LMR values indicate 
low and very low risk patients in the AFIP 
scoring system. 
In the light of the above statements, the use of 
adjuvant therapy in low-risk and very low-risk 
GIST patients was found to be unnecessary, but 
adjuvant therapy had a place in moderate and 
high-risk GIST patients. These risk groups can 
be determined by scoring systems. In our study, 
we found that the inflammatory indicators 
LMR, PLR and MWR obtained from 
preoperative blood values were compatible 
with AFIP. LMR, PLR and MWR values were 
statistically significant in predicting low and 
high risk patients according to AFIP 
interrogation system. When we evaluate ROC 
analysis, LMR, PLR and MWR can predict the 
low and very low risk patients in AFIP scoring 
system and we just found that the curve of LMR 
is significant.  
The limitation of our study was the limited 
number of patients. Another limiting factor was 
the retrospective study. The study should be 
supported with larger patient series. However, 
we think that the number of our studies for a 
rare disease such as GIST will not be 
underestimated. 
Conclusions 
As a result of our study, we think that LMR is 
effective in identifying low and very low risk 
patients compared to AFIP. From this point of 
view, we suggest that LMR can identify high 
and medium risk patients by excluding low and 
very low risk patients and may be an 
independent risk factor in GIST scoring 
systems. We think that low and very low risk 
patients who do not require adjuvant therapy 
according to AFIP scoring can be predicted by 
determining LMR values in the preoperative 
period. 
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